At a glance

Prostamax Quick Reference

Community range: 500mcg–1mg daily
Discussed for SubQ or IM injection
Cycle: 10–20 days
Community convention, not a tested human schedule
Sequence: KEDP
Lys-Glu-Asp-Pro tetrapeptide
Evidence base: Preclinical
Prostate outcomes studied in rat models

Overview

What Is Prostamax?

Prostamax is a synthetic four-amino-acid peptide with the sequence lysine–glutamic acid–aspartic acid–proline (KEDP). It belongs to a family of short peptide bioregulators explored for tissue-specific effects.

Two compound-specific rat studies investigated KEDP in experimental prostate inflammation and hyperplasia. Separate laboratory work examined its effects on chromatin in human lymphocytes. These are early signals, not evidence that Prostamax improves urinary symptoms, prostate size, or PSA in people.

The defined KEDP sequence also differs from animal-derived prostate extracts, which contain multiple peptides. Findings from those mixtures should not be attributed to Prostamax.

Mechanism

Prostamax Mechanism of Action

KEDP sequence

Prostamax is the defined Lys-Glu-Asp-Pro tetrapeptide, distinct from mixed prostate extracts.

Chromatin observations

Laboratory exposure of human lymphocytes changed measures of chromatin organization; clinical relevance is unknown.

Prostate tissue models

Rat studies reported less inflammatory infiltration and altered tissue remodeling after KEDP treatment.

Human translation

No controlled study has shown that these tissue effects improve human urinary symptoms or prostate health.

Research findings

Prostamax Benefits

These outcomes were measured in rat tissue or laboratory cells. They do not establish clinical prostate or urinary benefit.

Prostatitis Model

A rat study reported less swelling, vascular congestion, and lymphoid infiltration after KEDP treatment.

BPH Model

In a sulpiride-induced rat model, KEDP reduced prostate lateral-lobe mass and volume relative to untreated animals.

Tissue Remodeling

The prostatitis experiment also reported less collagen accumulation and fewer sclerotic or atrophic changes.

Chromatin Research

Small ex vivo studies of human lymphocytes investigated KEDP-related chromatin changes, without a demonstrated clinical outcome.

Protocol planning

Prostamax Dosing Protocol

Prostamax is discussed as a SubQ or IM injection, commonly for 10–20 days. No human dose-finding study validates a route, range, or cycle.

Members Access Only

Sign in or create a free account to view this content.

Preparation

Prostamax Reconstitution

Example concentration

20mg vial + 2mL bacteriostatic water

Result10mg/mL

Reconstitution steps

1

Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2

Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.

3

Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake.

4

Store

Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.

N=1 reports

Prostamax Community Experience

Positive Reports

Some users describe stronger urinary flow or less hesitancy.
Fewer nighttime bathroom trips are reported by some during or after a cycle.
Some report less pelvic pressure or a more complete-emptying sensation.

Negative & Mixed Reports

Many users notice little or no change.
Objective PSA, prostate-volume, and flow data are rarely provided with reports.
Injection-site irritation, headache, or fatigue also appear in anecdotes.

Stacking & synergy

Prostamax Stacking & Synergy

These are community pairings or clinical-context comparisons, not proven combinations.

Prostamax + Vesilute

A bioregulator pairing discussed around prostate and bladder research. Tracking urinary measures separately would help distinguish any perceived contribution.

Prostamax + Testagen

Both appear in male reproductive research discussions, but the pairing has not established changes in testosterone, fertility, or sexual function.

Prostamax + Prostate Medications

Alpha blockers and 5-alpha-reductase inhibitors can change urinary symptoms and PSA interpretation; clinician-guided monitoring remains essential.

Prostamax + TRT

Testosterone therapy can affect prostate monitoring, so any experiment belongs in the context of the prescribing clinician’s follow-up.

Safety notes

Prostamax Side Effects & Safety

No modern human safety trial has established Prostamax pharmacokinetics, adverse-event frequency, or long-term safety.

Community Reports

Injection-site redness, tenderness, bruising, or swelling.
Occasional headache, fatigue, dizziness, or nausea.
Some report temporary changes in urinary sensation.

Unresolved Risks

Effects on PSA, prostate tumors, fertility, and hormones are unknown.
Safety in urinary obstruction or kidney impairment has not been established.
Injectable quality, sterility, and repeated-cycle effects remain concerns.

Prostamax Precautions

Avoid or Discuss With a Clinician If

Known or suspected prostate cancer, or unexplained elevated PSA.
Acute urinary retention, fever, chills, blood in urine, or suspected infection.
Known hypersensitivity to Prostamax or a formulation ingredient.

Use Caution With

BPH, chronic prostatitis, or previous prostate surgery requiring evaluation.
Anticoagulant or antiplatelet therapy, which may increase injection bruising.
TRT or drugs that affect urinary flow or PSA interpretation.

Prostamax is not FDA approved for any human therapeutic indication.

Final verdict

Peptide Protocols Verdict on Prostamax

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Our opinionated opinion

Prostamax is a niche compound we find interesting because its research focuses on prostate tissue rather than a broad, vague longevity claim. Community feedback is mixed: some describe easier flow and fewer nighttime trips, while others notice nothing. We have not tried it ourselves because we do not have the symptoms that would give us a useful firsthand test.

That lack of personal experience matters to our rating. We can see why someone researching prostate bioregulators would look at KEDP, but we would not call it a reliable answer for urinary symptoms based on rat tissue findings and anecdotes. Any persistent or changing urinary symptoms deserve proper evaluation. For now, the focused preclinical signal earns a C, and the missing human outcomes keep it there.